PMID: 7027438Apr 1, 1981Paper

Immune suppression with cyclosporin A-optimism and caution

Scottish Medical Journal
A W Thomson, I D Cameron

Abstract

There have been no fundamental changes over the past 15 to 20 years in the immunosuppressive agents used in clinical transplantation. Equally efficient, but less toxic alternatives have been sought for some time. Cyclosporin A is an important new pharmacological immune suppressant, with a unique structure, which prolongs graft survival in a variety of species. It exerts a highly selective inhibitory effect on those T lymphocytes responding to antigenic challenge and is not myelotoxic. Indeed, no toxic effects have been reported at therapeutic doses in animals. Clinical trials indicate that it could prove extremely useful in management of graft rejection and autoimmune disease, however there are some doubts regarding possible hepatotoxic and nephrotoxic effects in man. There is also concern over the reported incidence of malignant lymphomas in cyclosporin A treated graft recipients.

References

Jul 1, 1976·Agents and Actions·J F BorelH Stähelin
Mar 10, 1979·Lancet·S W JamiesonN E Shumway
Apr 1, 1980·Transplantation·D C DunnB M Herbertson
Jan 5, 1980·British Medical Journal·R Y CalneD B Evans
Mar 1, 1980·The British Journal of Ophthalmology·W F ShepherdB R Jones
Mar 1, 1980·The International Journal of Applied Radiation and Isotopes·D M Taylor
Nov 1, 1980·Transplantation·L C McIntosh, A W Thompson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis
D Salomon, B Halioua
Zeitschrift für Rheumatologie
M EstefanW Müller
© 2021 Meta ULC. All rights reserved